A COMPARISON OF 1.5% GLYCINE AND 2.7% SORBITOL-0.5% MANNITOL IRRIGANTS DURING TRANSURETHRAL PROSTATE RESECTION
Purpose
We performed a prospective randomized trial comparing glycine 1.5% with 2.7% sorbitol-0.5% mannitol irrigating solution. We evaluated blood loss, fluid absorption, temperature change, cardiac effects and postoperative symptoms.
Materials and Methods
Between April 1998 and July 1999, 205 treated patients were included in the statistical analysis. Intraoperative irrigating fluid absorption was measured with the patient on the operating table. Serum cardiac troponin I was used as a marker of perioperative myocardial damage. Operative details were recorded, including the type of anesthesia, resection time and the weight of resected tissue. Postoperative symptoms were documented prospectively.
Results
Mean patient age was not significantly different in the glycine and sorbitol-mannitol groups. (72.1 versus 73.7 years). American Society of Anesthesiologists grade was also comparable. Median resection time was 27 minutes and resected tissue weighed a mean of 21 gm. The median resection rate was 0.8 gm. per minute. Blood loss and temperature changes during resection were similar in the 2 groups. Overall median blood loss was 216 ml. and irrigant absorption was 140 ml. In the sorbitol-mannitol group significantly less fluid was apparently absorbed during resection (median 88.2 versus 184.4 ml.). Analysis of the incidence of symptoms of the transurethral prostate resection syndrome did not show any differences in the irrigant groups. Cardiac damage measured using troponin I also showed no significant difference in the 2 groups, although there was a high overall incidence of 7.5%.
Conclusions
We noted no significant differences in 1.5% glycine and 2.7% sorbitol-0.5% mannitol as an irrigating solution for transurethral prostate resection.
Key Words: prostate , transurethral resection of prostate , sorbitol , mannitol , glycine
To access this article, please choose from the options below
Supported in part by Fresenius Kabi, Ltd.∥ Financial interest and/or other relationship with Sanofi Synthelabo, Gyrus Medical, Ltd. and Fresenius Kabi, Ltd.
PII: S0022-5347(05)65537-1
© 2001 American Urological Association, Inc. Published by Elsevier Inc All rights reserved.

